Schizophrenia-associated genetic loci identified in genome wide association studies and methods of use thereof

Patent metadata

Field	Value
Publication number	US-10100362-B2
Application number	US-201514853987-A
Country	US
Kind code	B2
Filing date	Sep 14, 2015
Priority date	Mar 14, 2013
Publication date	Oct 16, 2018
Grant date	Oct 16, 2018

Abstract

Compositions and methods for the identification of agents useful for the treatment of neurological disorders, including schizophrenia, are provided.

First claim

What is claimed is:

1. A method of treating schizophrenia (SCZ) or bi-polar (BP) disorder in a subject comprising:
a) obtaining genotype sequence information from nucleic acids obtained from a subject;
b) detecting in said information the presence of at least one SCZ or BP associated genetic alteration in NTRK3; and
c) treating the subject with at least one agent selected from ARRY470, ARRY872, AZ23, AZD6918, CE245677, DS6051, KT6587, LOXO101, PLX7486, RXDX101, and RXDX102.

2. The method of claim 1 , wherein the subject is treated with said at least one agent in combination with one or more additional agents selected from Serdolect, ABT126, ABT127, ABT925, Zoleptil, ABT354, Rexapin, Haloperidol lactate, Nuplazid, AM831, ACP104, Quetros, Aristab, Risperidone ACIS, Paxiprid, Loxapine succinate, Aripiprazole ,Zolafren, DA/5HT Modulator ADAMED, Kwetaplex, ADX63365, ADX50938, ADX71149, ATx11004, Cimicoxib Affectis, FazaClo, GlyT-1 inhibitor, Joykem, Alkepin, Ilopt, Invega Sustenna, Asenapine maleate AMNEAL, AG0098, APN1125, AVL3288, Apexidone, Clozapex, Ziprasidone Hydrochloride, Haloperidol decanoate, Apo-Clozapine, Apo-Pimozide, Ziprasidone Hydrochloride, Olanzapine ODF LABTEC, Dogmil, Zyprexa, Rispa, Amipride, Seronia, Seroquel, Huntexil, Zyprobiox, Fasoracetam, Risbiodal, Biopiprazole, Aripiprazole, Miradol, Fluphenazine decanoate, and Prochlorperazine edisylate.

3. The method of claim 1 , further comprising detecting a genetic alteration in at least one gene selected from neuromedin B, TSNARE1, MAD1L1, CACNA1D, NT5DC2, ITH1, NEK4 NIMA, GNL3, PB1, GLT8D1, FTSJ2, NUDT1, SNX8, SEC11A, SCAND2, ZSCAN2, ALPK3, PDE8A, GRIN2A, GRIN2B, DLG2, DLG1, DLG4, ATP2B2, NOS1, ERBB4, ANSK1B, CHUK, CNTN2, CNTNAP2, CUL3, CREB1, CREB5, EP300, GABBR2, GNA13, NCOR2, NTRK3, PAK2, PTK2, PTK2B, PTN, PTPRF, STK4, SEMA4C, PTPRG, MAPK8IP1, TIAM1, IRS1, and YWHAZ and TCF4.

Assignees

• Childrens Hospital Philadelphia

Inventors

• Hakonarson Hakon
• Sleiman Patrick
• Chang Xiao

Classifications

• G01N2500/10

  involving cells · CPC title

• C12Q2600/156

  Polymorphic or mutational markers · CPC title

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title

• G01N33/6803

  General methods of protein analysis not limited to specific proteins or families of proteins · CPC title

• G01N2800/302

  Schizophrenia · CPC title